Rolandic epilepsy (RE) is the most common idiopathic focal childhood epilepsy. Its molecular basis is largely unknown and a complex genetic etiology is assumed in the majority of affected individuals. The present study tested whether six large recurrent copy number variants at 1q21, 15q11. 26 , odds ratio 5 26.2, 95% confidence interval: 7.9 -68.2). In contrast, the 16p11.2 duplication was not detected in 1738 European epilepsy patients with either temporal lobe epilepsy (n 5 330) and genetic generalized epilepsies (n 5 1408), suggesting a selective enrichment of the 16p11.2 duplication in idiopathic focal childhood epilepsies (Fisher's exact test P 5 2.1 3 10
INTRODUCTION
Rolandic epilepsy (RE), also known as benign epilepsy with centrotemporal spikes (BECTS), is the most common childhood epilepsy with a prevalence of 0.2-0.73/1000 (i.e. 1/2500) (1-3). RE is related to rarer, and less benign epilepsy syndromes, including atypical benign partial epilepsy (ABPE), LandauKleffner syndrome (LKS) and epileptic encephalopathy with continuous spike-and-waves during sleep (CSWSS) (4-7), referred to as RE related syndromes, or atypical Rolandic epilepsy (ARE) by some authors (8) .Together RE and ARE are considered to form the spectrum of epilepsy-aphasia disorders with overlapping clinical characteristics. RE is located on the benign end of this spectrum and has an age-of-onset between 2 and 13 years with a mean onset around the age of seven (9, 10) . The cardinal clinical features of RE are brief, focal hemifacial or oropharyngeal sensorimotor seizures with speech arrest and secondarily generalized tonic-clonic seizures, which mainly occur during sleep. Classical RE usually takes a self-limiting course with seizures remitting spontaneously during adolescence. Although co-morbidities (e.g. learning and reading disabilities, behavioral issues, attention deficit hyperactivity disorder) are frequently reported in cohorts of children affected by RE, the long-term outcome is excellent (11, 12) . ABPE, CSWSS and LKS denote more severe forms of early-onset focal childhood epilepsies or epileptic encephalopathies with various additional seizure types, neurocognitive regression, autistic features or a regression of language with speech dyspraxia as in LKS (6, 13) . RE and ARE share the Electroencephalography (EEG) characteristic of centrotemporal spikes (CTS), blunt spikes of high-voltage and typical morphology. In ARE spikes become generalized during slow wave sleep and their morphology, location and background activity may vary to some extent (5, 8) . The CTS EEG trait is not entirely specific to RE, as it is also found in 2-4% of healthy children (14, 15) , in 10-28% of children with autism spectrum disorder (ASD) (16) (17) (18) and in the Fragile-X-Syndrome (19) .
The underlying etiologies of RE remain largely unknown although a genetic basis is postulated. Multiplex family studies suggested an autosomal dominant inheritance of the EEG trait CTS (20, 21) . However, several other arguments, among them the distribution of seizure-risk in relatives of patients with RE, argue for a complex mode of inheritance (22) . Linkage studies identified loci for CTS on 15q14 (LOD 3.56) and 11p13 (LOD 4.30) (23, 24) . Fine mapping of the latter locus revealed an association with the ELP4 gene, but causative mutations have not yet been identified (24) . Markers linked to chromosome 16p12-11.2 (LOD 3.68) were found in one family affected by RE with paroxysmal exercise-induced dystonia and writer's cramp (25) , while disease-associated variants in the SRPX2 gene were found in a family with X-linked RE, oral and speech dyspraxia and intellectual disability and in one patient with perisylvian polymicrogyria and Rolandic seizures (26) . Rare variants in KCNQ2 and KCNQ3 were identified in a small number of patients with RE (27) . Recently others and we showed that genomic alterations in GRIN2A, RBFOX1, RBFOX3 and DEPDC5 are genetic risk factors for idiopathic focal epilepsies with CTS, with and without language dysfunction (28) (29) (30) (31) (32) .
Copy number variants (CNVs) are an important source of structural genomic variation. Whereas many CNVs, especially non-recurrent ones, are not necessarily related to a clinical phenotype, six prominent recurrent CNVs (1q21, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and 22q11.2) are strongly associated with seizures and a range of neurodevelopmental and neuropsychiatric disorders including autism (33) (34) (35) (36) (37) (38) . One of the characteristic features of these recurrent CNVs is their remarkable phenotypic variability suggesting a shared genetic basis of the above diseases. The 16p11.2 600 kb BP4-BP5 microdeletion (OMIM #611913) is associated with ASD, obesity and intellectual disability with and without epilepsy, whereas the reciprocal duplication (OMIM #614671) is linked to schizophrenia, microcephaly, intellectual disability and being underweight (39 -45) . Recurrent microdeletions at 15q11.2, 15q13.3 and 16p13.11 have been identified as important risk factors for genetic generalized epilepsy (GGE) accounting for 1% of these patients but are also associated with a range of other neuropsychiatric symptoms (33, 34, 46) . Similarly, the 16p11.2 duplication was recently reported in two patients with RE with atypical electro-clinical features (47) . These pleiotropic effects and the associations between recurrent CNVs and GGE prompted us to investigate systematically the frequency of these six recurrent CNVs and novel large CNVs in a cohort of children with RE or ARE. In this study one we report a significant association of the recurrent 16p11.2 microduplication and a borderline association of the 15q11.2 duplication with typical and atypical RE. The 16p11.2 association was independently reproduced by phenotyping a large cohort of carriers of recurrent 16p11.2 structural variations, ascertained through learning impairment and behavioral disturbances, where the duplication but not the reciprocal deletion was associated with RE/ARE.
RESULTS

CNV detection
In our discovery cohort of 281 unrelated patients we identified CNVs at four of the six investigated recurrent candidate loci (15q11.2, 15q13.3, 16p11.2 and 22q11.2) (Table 1) as well as other CNVs (Table 2) .
We found a significant enrichment of 16p11. (44) . To confirm our findings we subsequently screened the 16p11.2 locus in an independent sample of 112 patients with RE/ARE. This screen revealed one 16p11.2 microduplication spanning 600 kb in size between breakpoints BP4/BP5 (Fig. 1) Fig. S1 ; of note this smaller 110 kb duplication was not considered for the statistical analysis).
The present association of the 16p11.2 duplication with RE/ARE is further supported by a recent genome-wide CNV study that observed 16p11.2 duplications in two out of 47 RE patients [47] . To evaluate the previously reported prevalence of 16p11.2 duplications in the German population we examined array data from an additional cohort of 2256 healthy individuals from Germany (KORA, PopGen) unscreened for epilepsy (52) but did not detect any 16p11.2 rearrangements. This is in accordance with previous data reporting a prevalence of the 16p11.2 duplication of 0.05% in the European population (31 duplications out of 58 635 tested individuals) (45) . A meta-association analysis of all available data (including two published patients) (47) ). We also identified a nominally significant increase of duplications at the 15q11.2 locus (approximate genomic coordinates according to hg19 chr15:22750000 -23350000) in our discovery cohort. Six patients displayed the duplication in comparison to 8 out of 1512 controls (Fisher's exact test, P ¼ 0.014, OR ¼ 4.1; 95% CI: 1. 16 -13.59 ). This borderline association did not remain significant after Bonferroni correction for multiple comparisons.
Clinical data and segregation analysis
Patients harboring the 16p11.2 duplication either suffered from typical RE (n ¼ 5) or atypical RE (n ¼ 1) (Table 3 ). Three (45) . No data were available on the BMIs of the remaining duplication carriers and on head circumferences of all patients. The duplications were inherited in all four cases where testing was possible ( Fig. 2 ) with a maternal transmission in three of them. The smaller 110 kb atypical duplication was inherited from the father who himself had a history of febrile seizures (Family 5). While the classical 600 kb duplication co-segregated with RE in one family (Family 2), two other families displayed reduced penetrance with reportedly unaffected mothers carrying the duplication (F1-I.2 and F4-I.2). We could not determine whether these mothers did exhibit the RE-characteristic EEG trait during their childhood. Family 1 is interesting as it demonstrates the variability of the phenotypes in the duplication carriers, as the index case (F1-II.1) was affected by severe ARE/LKS, while his younger sister only displayed CTS in EEG (F1-II.3). Notably, the third sibling in this family (F1-II.2) presented the EEG trait without being a duplication carrier (Fig. 2) . This family is not only affected by the 16p11.2 duplication but, as recently reported, also carries a novel p.C231Y GRIN2A mutation (28) . Whereas the GRIN2A variation segregates with the CTS trait, the 16p11.2 duplication does not seem to be necessary for the electro-clinical component of the phenotype. In Family 4, we detected in addition to the 16p11.2 duplication a novel missense variation of unknown significance in DEPDC5, a gene, which was recently identified in genetic focal epilepsies (54, 55) and also identified by us to be mutated in genetic focal childhood epilepsies (32) . In this family the 16p11.2 duplication was inherited from the unaffected mother and the DEPDC5 variant from the unaffected father, resulting in a potentially increased mutational load in the child. In individual F3-II.1 we identified a second large duplication ( 1. Table S1 ). In the duplication group, three individuals were diagnosed with RE/ARE (Supplementary Material, Table S2 ). One patient presented with typical RE (short nocturnal motor facial seizures and centrotemporal spikes activated by sleep). He also suffered from reading and spelling difficulties and was diagnosed with an attention deficit disorder. The second patient displayed the same electro-clinical features but, in addition, also presented with a delay of language, a behavioral disorder, a borderline IQ (75) and an early age of onset (2 years of age). He was therefore diagnosed as atypical RE. The third patient displayed an ARE-epileptic encephalopathy (initially CSWSS, but eventually language regression and ASD traits which led to the diagnosis of LKS). An additional (fourth) patient had only CTS activated by sleep without seizures. In the deletion group, a single patient had CTS activated by sleep without seizures but none suffered from RE/ARE. Hence RE/ARE occurred only in duplication carriers (2.6% n ¼ 3/117) but not in deletion carriers (n ¼ 0/202) (Fisher's exact test, P ¼ 0.05). Although it was not possible to assess the exact prevalence of RE/ARE in the complete cohorts screened (i.e. including cases without 16p11.2 rearrangements), we note that RE/ARE features are enriched 25-fold in the 16p11.2 duplication cohort as compared with the general population given an RE-prevalence of 0.05% (45) .
Other structural rearrangements
To investigate whether other large CNVs beyond the above six candidate regions were present in our RE/ARE patients we performed a genome-wide screen for CNVs larger than 500 kb in all 281 individuals of the discovery cohort. In particular, we were interested whether 16p11.2 duplication carriers might display additional large CNVs. We found 23 additional CNVs in the 281 RE/ARE patients screened ( Table 2 ). Six of these CNVs were partially overlapping with CNVs previously reported in patients with epilepsy (48) (49) (50) (51) 56, 57) . With the exception of one duplication mapping to chromosome 12q24.33, which was identified in two patients and in two out of 1512 controls from the discovery cohort, all other CNVs occurred as single events in our dataset. Apart from individual F3.II.1, no other 16p11.2 duplication carrier harbored an additional large CNV.
DISCUSSION
We report a highly significant association of the recurrent 16p11.2 microduplication with RE/ARE spectrum epilepsies. We detected the 600 kb 16p11.2 duplication in 1.3% of RE-patients (i.e. in five unrelated individuals: in a sixth unrelated patient we discovered a smaller 110 kb atypical rearrangement, which was not included in the statistical analysis). This corresponds to an enrichment of .25-fold when compared with the prevalence in the general population (0.05%) (45) . During the preparation of this manuscript, a genome-wide CNV analysis revealed hemizygous 16p11.2 duplications in two out of 47 RE/ARE patients (47) . This CNV report strengthens our association claim. Meta-analysis of the joint RE/ARE cohorts and the assembly of multiple publicly available control cohorts highlights a significant excess of the 600 kb 16p11.2 duplication in RE/ARE patients (7/440 RE/ARE patients versus 32/65 046 controls, P ¼ 7.53 × 10
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). Notably, the observed OR of 32.8 might be overestimated given that our cohorts partly included RE/ARE patients (98 of 393 patients) with a positive family history. However, such a bias seems to be small in this study as the majority of patients (75%) were enrolled irrespective of their family history and as the frequency of the duplication carriers was similar in the multiplex and singly ascertained cohorts (4/295 and 2/98 respectively). Given that we observed a significant enrichment of 16p11.2 duplications in RE/ARE patients but not in other common epilepsy syndromes, such as GGEs or mesial temporal lobe epilepsies (mTLEs), our findings implicate a selective contribution of the 16p11.2 duplication to the genetic variance of RE/ARE. Future studies on larger cohorts are required to delineate the phenotypic spectrum of epilepsies associated with the 16p11.2 duplication. Although the effect size appears considerable, the penetrance is incomplete as illustrated by the presence of clinically apparently unaffected duplication carriers in our families (with the caveat that mild childhood phenotypes might have been missed or not reported in adult carriers). Likewise, the severity and expressivity of the phenotypes varied considerably between affected members of the same family. Similar observations have been made with other CNVs that are nevertheless firmly established as risk factors for epilepsies (33) . One remarkable feature of the 16p11.2 rearrangements is the wide diversity of the associated phenotypes. The BP4-BP5 duplication and its reciprocal deletion were previously associated with schizophrenia, micro-/ macrocephaly and underweight/obesity mirror phenotypes as well as impairment in cognitive performance (39, 40, 42, 43, 45) .
The 16p11.2 duplication is also a known risk factor for ASD (58) , emphasizing the often discussed link between autism and epilepsy. Autistic features are frequently detected in severe forms of epilepsy associated with mental retardation and language regression (59 -61) and conversely the prevalence rates of epilepsy in ASD is increased up to 46% (62) . In our RE/ ARE cohort, neither the five 600 kb 16p11.2 duplication carriers nor the 110 kb duplication proband exhibited ASD traits, while a single individual from the 16p11.2 rearrangement cohort, diagnosed with LKS, displayed the autistic signs typical for this syndrome. Our present findings raise questions which warrant further studies as the data described here do not allow a definite distinction between these possibilities. How does the 16p11.2 duplication variation predisposes to both RE and autism? Is it by increasing the risk to a combined phenotype (e.g. by affecting the same gene(s) located in both intertwined disease pathways)? Or are eventually the two phenotypes just coincidentally related to each other due to the involvement of separate genes within the duplication.
In the present report we extend further the list of neurodevelopmental disorders associated with the recurrent 16p11.2 CNV with the full spectrum of the RE/ARE phenotype ranging from mild RE cases to severe forms of ARE with epileptic encephalopathies. Fitting with clinical observations which have long suggested a shared etiology between RE and a wide spectrum of other neuropsychiatric syndromes and symptoms (e.g. cognitive deficits, language disorders, ASD, attention deficit hyperactivity disorder) (12, 63) we have identified the 16p.11.2 duplication as one shared genetic susceptibility factor. Given the phenotypic variability modulating genetic variants should be expected and consistently such additional genetic factors were identified in three of our families. The exact phenotype of a 16p11.2 duplication carrier would thus depend on the genetic background and additional environmental factors. Elucidating their roles warrants future research.
The 600 kb long chromosomal region between BP4 and BP5 on 16p11.2 contains 28 'unique' genes (SPN, QPRT, C16orf54, ZG16, KIF22, MAZ, PRRT2, PAGR1 (aka C16orf53), MVP, CDIPT, CDIPT-AS, SEZ6L2, ASPHD1, KCTD13, TMEM219, TAOK2, HIRIP3, INO80E, DOC2A, C16orf92, FAM57B, ALDOA, PPP4C, TBX6, YPEL3, GDPD3, MAPK3, CORO1A) and multiple copies of BOLA2/2B, SLX1A/1B, SULT1A3/4 and NPIPL3 (Fig. 1) . Most of these genes are expressed in the brain and might thus contribute singly or jointly to the etiology of RE and related disorders. Several studies on model organisms have attempted to narrow down the dosage sensitive genes for the observed brain-related traits. Haploinsufficiency of ALDOA and KIF22 have been related to changes in brain morphology in zebrafish (64) , while alterations in head size anticorrelated with levels of KCDT13, MAPK3 and MVP in teleosts and rodents (65) . One particularly interesting candidate is the PRRT2 gene with a putative role in synaptic vesicle functioning, as it has been associated with a range of different childhood epilepsies. Mutations in PRRT2 are, for instance, the main cause of benign familial infantile seizures (BFIS) and other infantile epilepsy syndromes as well as paroxysmal kinesigenic dyskinesia (66 -70) . Although atypical CNVs in the 16p11.2 interval are rare they are valuable in narrowing down the critical genomic interval. We detected one partial 110 kb duplication excluding PRRT2 but encompassing SPN, QPRT and C16orf54 in a patient who suffered from RE. The QPRT gene is of interest as it encodes an enzyme (quinolinate phosphoribosyltransferase), which converts quinolinic acid to NAD+ and thus detoxifies this excitotoxic compound (71, 72) . Intracerebral injection of quinolinic acid causes seizures in mice (73) and elevation of quinolinate levels in the human brain is associated with neurodegenerative disorders (74, 75) . While dosage differences in QPRT might explain the observed phenotype, this single, isolated rearrangement does not allow us to draw any firm conclusions, especially as we do not have any information on the CTS status of the single previously reported additional individual, who carried a partially overlapping 136 kb duplication, encompassing the QPRT gene (45) .
Of interest, the detected borderline association of the 15q11.2 duplication with RE/ARE is supported when the comparison is made with its previously reported frequency in the general population (36) (6/281 cases versus 44/9841 controls, Fisher's exact test, P ¼ 0.0025). Hopefully, this finding will encourage further studies on larger RE/ARE cohorts to assess whether the 15q11.2 duplication really confers risk of RE/ARE.
In conclusion, we have identified 16p11.2 duplications as an important genetic risk factor for RE/ARE with 1.53% of patients carrying the variation. Our results suggest that the 16p11.2 duplication selectively confers susceptibility for RE/ARE but not for other common epilepsy syndromes, such as GGEs or TLE. An interesting but unresolved point concerns the role of additional genetic factors modulating the penetrance and the variable clinical features of the disease. Future studies on other well phenotyped cohorts could shed more light on these open issues.
MATERIALS AND METHODS
Study participants
In a multi-center effort 393 RE/ARE patients were recruited from Austria (n ¼ 160), Germany (n ¼ 134), Australia (n ¼ 78) and Canada (n ¼ 21). Diagnosis of RE was performed according to the International Classification of Seizures and Epilepsies (76) . The various related types of atypical RE were diagnosed as specified previously (4, 5, 77) . In the discovery cohort 98 of the patients were ascertained via multiplex-families with the minimum criteria of at least two affected siblings. The index case had to be diagnosed with RE or ARE, and the affected sibling(s) either with RE, ARE or the EEG trait only. All other 183 were RE/ARE patients recruited consecutively at the participating clinics, as soon as the diagnosis of RE/ARE was present, irrespective of their family history for seizures. The discovery set thus included a total of 281 unrelated patients of Caucasian ancestry affected by RE (n ¼ 230) and ARE (n ¼ 51) (165 males and 116 females), and 1512 unscreened German population controls (755 males and 757 females) examined by the same array type. The confirmation cohort consisted of 112 unrelated patients with RE (n ¼ 109) and ARE (n ¼ 3) (63 males and 49 females), from Australia (n ¼ 78) and Austria (n ¼ 34) ascertained through the diagnosis of RE/ARE irrespective of whether they had a family history of seizures. Additional SNP-array data (Affymetrix Genome-Wide Human SNP Array 6.0) were obtained from 1408 GGE patients, 330 mTLE patients and 2256 German population controls (KORA: n ¼ 1250, POGEN: n ¼ 1006). We also studied 319 children carrying a 600 kb 16p11.2 rearrangement. These patients were assembled by screening neurodevelopmental disorders cohorts through a network of cytogenetic centers (44, 45) . For summarized description of all cohorts see Supplementary Material, Table S3 . Written informed consent was obtained from all participating patients and, when appropriate, from both parents and adolescents. This study was approved by all respective local institutional review boards.
Genotyping, copy number variation detection and validation
CNVs were detected by high-density SNP genotyping arrays (Illumina HumanOmniExpress BeadChip) and subsequent CNV calling was carried out with the PennCNV software (78) . CNVs were considered to match published recurrent CNVs if they overlapped at least 80% of the respective CNV-length. All called recurrent candidate CNVs were .350 kb in size and covered with 100-756 consecutive SNP-probes. Smaller CNVs of at least 50 kb nested within the recurrent candidate regions were considered if they included one of the previously proposed candidate genes (33, 46) . Genome-wide CNV screening beyond the six candidate regions was restricted to CNVs with a segment size .500 kb (79) and a minimum of 50 markers to achieve a high accuracy and reproducibility of CNV callings across different array platforms, laboratory sites and calling algorithms (80) . CNVs were manually inspected in the Illumina Genome Viewer Software for the regional SNP heterozygosity state (BAF) and log2 ratios of the signal intensities (LRR). One thousand five hundred and twelve controls genotyped on Illumina HumanOmniExpress BeadChip and 330 mTLE patients genotyped on IlluminaHap550 array were analyzed with PennCNV. Regions of CNVs detected in patients were manually inspected in the control samples for the presence of duplications and deletions. CNV calling of the 16p11.2 rearrangements in the 2256 German control subjects was performed by the Affymetrix SNP 6.0 array as previously reported (33, 52) . Recurrent CNV validation and segregation in families was performed with real-time quantitative PCR (qPCR) using TaqMan CNV probes (Supplementary Material, Table S5 ; Life Technologies, Darmstadt, Germany) and custom array-CGH for the 16p11.2 duplication (Agilent Technologies, Santa Clara, CA). This custom array contains about 544 probes in the 16p11.2 region (chr16:29500000 -30200000, hg19) with an average probe spacing of 1.3 kb.
